Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14800725 | 0.88 | MAPT (0.45) | MAOBMAPTERBB2SMN1; SMN2 | |
| SCHEMBL14801382 | 0.88 | TNIK (0.42) | FFAR1FFAR4ALDH1A1ERBB2SMN1; SMN2 | |
| SCHEMBL14804131 | 0.86 | FFAR1 (0.42) | FFAR1FFAR4MAOBMAOAMIF | |
| SCHEMBL14800428 | 0.76 | TNIK (0.40) | FFAR1FFAR4MAOBMAPTERBB2 | |
| SCHEMBL14818895 | 0.76 | TNIK (0.40) | FFAR1FFAR4ERBB2MET | |
| SCHEMBL17260683 | 0.71 | TP53 (0.53) | ALDH1A1MAPTL3MBTL1SMN1; SMN2MET | |
| SCHEMBL17260686 | 0.67 | ACHE (0.52) | MAOBMAOAMIFACHEALDH1A1 | |
| SCHEMBL14804157 | 0.67 | MAPT (0.49) | FFAR1FFAR4MAPTSMN1; SMN2 | |
| SCHEMBL14804144 | 0.65 | HDAC3 (0.42) | MAOBALDH1A1MAPT | |
| SCHEMBL20792818 | 0.62 | JAK1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841301-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130079338-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079338-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | FFAR1 415/4885FFAR4 704/4885MAOB 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.